Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RDEA 594 and allopurinol in patients with gout.

Trial Profile

RDEA 594 and allopurinol in patients with gout.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allopurinol (Primary) ; Allopurinol/lesinurad (Primary)
  • Indications Gout
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2010 Results reported in an Ardea Biosciences media release.
    • 21 Jun 2010 New trial record
    • 19 Jun 2010 Interim results presented at the Annual European Congress of Rheumatology in June 2010, according to an Ardea Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top